Page 395 - WSAVA2017
P. 395

In the future, veterinary medicine will see the development of additional therapeutic mAbs for companion animals and other species. These highly targeted and safe therapeutics are likely to prove beneficial to treat diseases uniquely without the side effects associated with traditional broad-spectrum pharmacotherapy.
Bammert G, Dunkle B, Fici G, et al. Identification and characterization of anti- canine interleukin-31 neutralizing monoclonal antibodies [abstract]. Vet Dermatol. 2014;25:404.
Dunham S, Teel J, Bammert G, et al. Evaluation of anti-IL-31 monoclonal antibodies in a model of IL-31-induced pruritus in Beagle dogs [abstract]. Vet Dermatol. 2014;25:403.
Gearing DP, Huebner M, Virtue ER, et al. In vitro and in vivo characterization of a fully felinized therapeutic anti-nerve growth factor monoclonal antibody for the treatment of pain in cats. J Vet Intern Med. 2016;30(4):1129-1137.
Gearing DP, Virtue ER, Gearing RP, et al. A fully caninised anti-NGF monoclonal antibody for pain relief in dogs. BMC Vet Res. 2013;9:226.
Gonzales AJ, Humphrey WR, Messamore JE. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-e12.
Gruen ME, Thomson AE, Griffith EH, et al. A feline-specific anti-nerve growth factor antibody improves mobility in cats with degenerative joint disease– associated pain: a pilot proof of concept study. J Vet Int Med. 2016;30(4):1138- 1148.
Michels GM, Ramsey DS, Walsh KF, et al. (2016) A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol. 2016;27:478-e129.
Olivry T, Bainbridge G. Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. Clinician’s Brief. 10 Mar 2015. www.itchcycle. com/antibodytherapy
An Urban Experience

   393   394   395   396   397